98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0284185119837932 | DOI Listing |
J Appl Clin Med Phys
September 2025
Cancer Control Program, Ministry of Health, Riyadh, Saudi Arabia.
Background: Mammography is a critical tool for early breast cancer detection, but its use of ionizing radiation necessitates careful monitoring and optimization of patient exposure to ensure safety. Conventional methods for reporting diagnostic reference levels (DRLs) rely on wide compressed breast thickness (CBT) ranges, which lack the precision to account for individual variations, limiting their effectiveness in optimizing mammographic radiation doses.
Purpose: To develop an equation-based approach that provides a DRL for any given CBT.
Abdom Radiol (NY)
February 2024
Department of Radiology, Chongqing Hospital of Traditional Chinese Medicine, No.6, Panxi 7th Road, Jiangbei District, Chongqing, 400021, People's Republic of China.
Purpose: To assess the characteristics of pancreatic perfusion in normal pancreas versus cirrhotic patients using intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI).
Methods: A total of 67 cirrhotic patients and 33 healthy subjects underwent IVIM on a 3.0 T MRI scanner.
Magn Reson Med
November 2023
Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Purpose: This paper presents a hierarchical modeling approach for estimating cardiomyocyte major and minor diameters and intracellular volume fraction (ICV) using diffusion-weighted MRI (DWI) data in ex vivo mouse hearts.
Methods: DWI data were acquired on two healthy controls and two hearts 3 weeks post transverse aortic constriction (TAC) using a bespoke diffusion scheme with multiple diffusion times ( ), q-shells and diffusion encoding directions. Firstly, a bi-exponential tensor model was fitted separately at each diffusion time to disentangle the dependence on diffusion times from diffusion weightings, that is, b-values.
Purpose: Model-based tumor growth inhibition (TGI) metrics are increasingly incorporated into go/no-go decisions in early clinical studies. To apply this methodology to new investigational combinations requires independent evaluation of TGI metrics in recently completed Phase III trials of effective immunotherapy.
Patients And Methods: Data were extracted from IMpower150, a positive, randomized, Phase III study of first-line therapy in 1,202 patients with non-small cell lung cancer.
Clin Transl Sci
March 2023
Gilead Sciences, Inc., Foster City, California, USA.
Cilofexor is a nonsteroidal farnesoid X receptor (FXR) agonist being evaluated for treatment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). This work characterized the pharmacokinetics, pharmacodynamic, safety, and tolerability of cilofexor in healthy participants. Cilofexor single and multiple once-daily doses (10 to 300 mg fasting or fed and twice-daily doses [15 and 50 mg; fed]; tablet formulation) were evaluated.
View Article and Find Full Text PDF